Haemonetics
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell Haemonetics and other ETFs, options, and stocks.About HAE
Haemonetics Corp. engages in the development and distribution of hematology products and solutions. It operates through the following segments: Plasma, Blood Center, and Hospital.
HAE Key Statistics
Stock Snapshot
As of today, Haemonetics(HAE) shares are valued at $68.36. The company's market cap stands at 3.29B, with a P/E ratio of 19.94.
On 2025-11-08, Haemonetics(HAE) stock traded between a low of $66.82 and a high of $71.36. Shares are currently priced at $68.36, which is +2.3% above the low and -4.2% below the high.
Haemonetics(HAE) shares are trading with a volume of 3.17M, against a daily average of 1.18M.
In the last year, Haemonetics(HAE) shares hit a 52-week high of $94.99 and a 52-week low of $47.32.
In the last year, Haemonetics(HAE) shares hit a 52-week high of $94.99 and a 52-week low of $47.32.
HAE News
Haemonetics Corporation recently reported second-quarter earnings results, revealing sales of US$327.32 million and net income of US$38.68 million, with both ba...
Haemonetics ((HAE)) has held its Q2 earnings call. Read on for the main highlights of the call. Meet Your ETF AI Analyst Discover how TipRanks' ETF AI Analyst c...
Key Points It was something of an outlier in booking gains on a bearish day for stocks overall. This was the result of an investor-pleasing quarterly earnings...
Analyst ratings
82%
of 11 ratingsMore HAE News
BofA upgraded Haemonetics (HAE) to Neutral from Underperform with a price target of $75, up from $58. Plasma volume growth returned to high single digits in the...
Haemonetics Corporation ( ) shares have had a really impressive month, gaining 36% after a shaky period beforehand. Unfortunately, the gains of the last month d...
Earnings Call Insights Haemonetics raises 2026 guidance, projects 7%–10% organic growth ex CSL amid strong plasma and hospital performance Nov. 07, 2025 3:27 AM...
(RTTNews) - Haemonetics Corp (HAE) revealed a profit for its second quarter that Increases, from last year The company's bottom line came in at $38.68 million,...
Needham analyst Michael Matson maintained a Buy rating on Haemonetics today and set a price target of $78.00. Meet Your ETF AI Analyst Discover how TipRanks' ET...